{Economic Information Daily, 20th} Hansoh Pharma (03692) is currently up 2.7%, trading at HK$32.6, with approximately 420,000 shares traded, involving HK$13.76 million.
Hansoh Pharma announced that it has entered into a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd (Roche), covering a portfolio consisting of a series of antibody-drug conjugate (ADC) projects. The group will receive a $400 million upfront payment and a $110 million one-year anniversary payment, and is eligible to receive potential milestone payments exceeding $1.5 billion based on the development, registration, and commercialization progress of the relevant projects, as well as tiered royalties based on future potential product sales.
The collaboration includes two preclinical ADC projects from Hansoh and multiple ADC projects targeting indications proposed by Roche and developed using Hansoh's proprietary ADC technology platform. The group will lead the early development of the relevant projects, up to and including the completion of global Phase Ia clinical trials. Roche will be responsible for further global development outside of China, Hong Kong, Macau, Taiwan. The group retains all rights to develop, register, and commercialize the projects within China, Hong Kong, Macau, and Taiwan.
The group also has the option to designate up to two projects to participate in their development outside of China, Hong Kong, Macau, and Taiwan, and as a return on such investment, is eligible to receive additional commercialization proceeds from these two projects in the United States.
Currently, the Hang Seng Index stands at 23,990, down 196 points or 0.8%, with turnover on the main board exceeding HK$3.1 billion. The Hang Seng China Enterprises Index stands at 8,078, down 49 points or 0.6%. The Hang Seng Tech Index stands at 4,055, down 52 points or 1.3%. (vs)
Hansoh Pharma announced that it has entered into a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd (Roche), covering a portfolio consisting of a series of antibody-drug conjugate (ADC) projects. The group will receive a $400 million upfront payment and a $110 million one-year anniversary payment, and is eligible to receive potential milestone payments exceeding $1.5 billion based on the development, registration, and commercialization progress of the relevant projects, as well as tiered royalties based on future potential product sales.
The collaboration includes two preclinical ADC projects from Hansoh and multiple ADC projects targeting indications proposed by Roche and developed using Hansoh's proprietary ADC technology platform. The group will lead the early development of the relevant projects, up to and including the completion of global Phase Ia clinical trials. Roche will be responsible for further global development outside of China, Hong Kong, Macau, Taiwan. The group retains all rights to develop, register, and commercialize the projects within China, Hong Kong, Macau, and Taiwan.
The group also has the option to designate up to two projects to participate in their development outside of China, Hong Kong, Macau, and Taiwan, and as a return on such investment, is eligible to receive additional commercialization proceeds from these two projects in the United States.
Currently, the Hang Seng Index stands at 23,990, down 196 points or 0.8%, with turnover on the main board exceeding HK$3.1 billion. The Hang Seng China Enterprises Index stands at 8,078, down 49 points or 0.6%. The Hang Seng Tech Index stands at 4,055, down 52 points or 1.3%. (vs)
